Premium
P2‐321: CLINICAL CHARACTERISTICS OF NONAMNESTIC MILD COGNITIVE IMPAIRMENT: A SINGLE‐CENTER EXPERIENCE
Author(s) -
Ko Hak Cheol,
Rhee Hak Young,
Park Key-Chung,
San Lee Jin
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.2728
Subject(s) - dementia , neuropsychology , medicine , clinical dementia rating , single center , rating scale , cognition , cognitive impairment , disease , psychology , psychiatry , developmental psychology
Background: Alzheimer’s Disease (AD) is not only more frequent and has an earlier onset in Down Syndrome (DS) than in the general population, but also has an atypical clinical phenotype and an uncertain genetic risk factor and biomarker profile. The aim of this study is to investigate clinical, genetic and biomarker aspects of AD in DS. Methods: Longitudinal 3-year follow-up of 20 symptomatic and asymptomatic subjects with DS aged between 18 and 60 years-old by means of cognitive assessment (CamdexDS), brain MRI, brain FDG and PiB-PET, CSF levels of Ab42, phosphorylated t and total t, genotyping of APOE and TREM2 polymorphisms. Results: Twelve individuals entered the study population. The group consisted of 4 cognitively impaired individuals (33%), 4 individuals suffering from psychiatric disorders (33%) and 4 normal controls (33%). Mean age was 43 yo (20-56 yo). Sixty-seven percent (n1⁄48) were males. Six individuals (3 males, 3 females) completed baseline assessment so far. Free trisomy 21 was confirmed by karyotype in all cases. From this subpopulation, 1 individual was demented, 4 suffered from psychiatric disorders and 1 was a normal control. All individuals refused to undergo lumbar puncture, and 2 of them refused to perform brain FDG and PiB-PET (including the demented participant). Mean total Camdex-DS score was 58 points over 109. The highest score (88) corresponded to the normal control participant. The lowest score (29/109) was attained by the only demented participant, being orientation, memory and praxis the most impaired cognitive domains. Cerebral PiB-PET was negative in all subjects (n1⁄44) and cerebral FDG-PET findings were non-specific. Conclusions: These are preliminary results as IASDA has recently started. Considering raising life expectancy in DS, AD in this population is not only a medical research topic, but also a public health issue. Several international efforts in North America and Europe are currently underway to excel research in this area. IASDA represents, to our knowledge, the first comprehensive initiative to evaluate AD in a Latin American DS population. Additionally, IASDA leads to the creation of the first DS-specific biobank in Argentina.